The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma: a double blind crossover study
- PMID: 3816096
The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma: a double blind crossover study
Abstract
The effectiveness of nifedipine in the treatment of Raynaud's syndrome was assessed in 16 patients with systemic sclerosis or a variant of this condition. Changes in finger and forearm blood flow (venous occlusion plethysmography), skin temperature and digital systolic pressure were measured both during the acute period and after a 2-week treatment. Subjective assessment of efficacy was based on patient diary data. Finger blood flow increased significantly both during the acute period and after 2 weeks of nifedipine therapy compared to placebo (P less than 0.05). Digital skin temperature also increased during the study period (P less than 0.01). Forearm blood flow and digital systolic pressure did not change. Nifedipine significantly reduced the frequency (P less than 0.05), duration (P less than 0.05) and severity (P less than 0.01) of attacks. Eleven out of the sixteen patients experienced side effects while on nifedipine. These results suggest that nifedipine is of benefit in the treatment of Raynaud's syndrome in patients with systemic sclerosis over a short time course.
Similar articles
-
Nifedipine in Raynaud's phenomenon: relationship between immediate, short term and longterm effects.J Rheumatol. 1987 Apr;14(2):284-90. J Rheumatol. 1987. PMID: 3598997 Clinical Trial.
-
Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.J Rheumatol. 1992 Sep;19(9):1407-14. J Rheumatol. 1992. PMID: 1279170 Clinical Trial.
-
Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon: a double blind placebo controlled trial.J Rheumatol. 1987 Apr;14(2):278-83. J Rheumatol. 1987. PMID: 3298649 Clinical Trial.
-
Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers.Am J Cardiol. 1985 Jan 25;55(3):154B-157B. doi: 10.1016/0002-9149(85)90625-3. Am J Cardiol. 1985. PMID: 3881908 Review.
-
Management of systemic sclerosis--a review.Singapore Med J. 1990 Jun;31(3):269-72. Singapore Med J. 1990. PMID: 2203150 Review.
Cited by
-
Wound, pressure ulcer, and burn guidelines (2023)-4: Guidelines for the management of connective tissue disease/vasculitis-associated skin ulcers, third edition.J Dermatol. 2025 Jun;52(6):e430-e480. doi: 10.1111/1346-8138.17703. Epub 2025 Apr 28. J Dermatol. 2025. PMID: 40292847 Free PMC article. No abstract available.
-
A double-blind cross-over study of nifedipine retard in patients with Raynaud's phenomenon.Clin Rheumatol. 1988 Sep;7(3):359-65. doi: 10.1007/BF02239193. Clin Rheumatol. 1988. PMID: 3067954 Clinical Trial.
-
A patient-centered approach to the burden of symptoms in patients with scleroderma treated with Bosentan: A prospective single-center observational study.Exp Ther Med. 2020 Mar;19(3):1739-1746. doi: 10.3892/etm.2019.8361. Epub 2019 Dec 20. Exp Ther Med. 2020. PMID: 32104228 Free PMC article.
-
Calcium channel blockers for primary Raynaud's phenomenon.Cochrane Database Syst Rev. 2016 Feb 25;2(2):CD002069. doi: 10.1002/14651858.CD002069.pub5. Cochrane Database Syst Rev. 2016. PMID: 26914257 Free PMC article.
-
Management of Raynaud's phenomenon. Focus on newer treatments.Drugs. 1989 May;37(5):700-12. doi: 10.2165/00003495-198937050-00005. Drugs. 1989. PMID: 2663416 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical